Tolvaptan: A new tool for the effective treatment of hyponatremia in psychotic disorders

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 4, 2010, Pages 637-648

  Josiassen, Richard C ^a,b   Curtis, Jessica ^b,c   Filmyer, Dawn M ^b   Audino, Brett ^b   Skuban, Nina ^d   Shaughnessy, Rita A ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Translational Neuroscience LLC   (United States)

^c Montgomery County Community College   (United States)

^d Worldwide Clinical Trials   (United States)

Author keywords

Hyponatremia; Osmotic demyelination; Psychogenic polydipsia; SAMSCA; Schizophrenia; Syndrome of inappropriate secretion of antidiuretic hormone (SIADH); Tolvaptan (OPC 41061); Vasopressin V2 receptor antagonist; Water intoxication

Indexed keywords

CONIVAPTAN; FUROSEMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; MOZAVAPTAN; PLACEBO; SAMSCA; SATAVAPTAN; SODIUM CHLORIDE; TOLVAPTAN; UNCLASSIFIED DRUG;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEHYDRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; HYPONATREMIA; HYPOTENSION; LIFE EXPECTANCY; MORBIDITY; PREVALENCE; PSYCHOSIS; REVIEW; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; BENZAZEPINES; COMORBIDITY; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; PREVALENCE; PSYCHOTIC DISORDERS; RECEPTORS, VASOPRESSIN;

EID: 77249108996     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003610656     Document Type: Review

References (78)

1. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-9
2. Verbalis JG. The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. In: Schrier RW, editor, Diseases of the kidney and urinary tract. Lippincott, Williams & Wilkins, Philadelphia, PA; 2007. p. 2214-48
3. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003;37:1694-702
4. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003;17:471-503
5. Fraser CL, Arieff AI. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997;102:67-77
6. Adrogue HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol 2005;25:240-9
7. Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine 1976;55:121-9
8. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(Suppl 11A):1-21
9. Siegel AJ, Verbalis JG, Clement S, et al. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med 2007;120:461 e11-461.17
10. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72
11. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalize patients. Endocrinol Metab Clin North Am 2003;32:459-81
12. Anderson RJ, Chung HM, Kluge R, et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164-8
13. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000;11:406-10
14. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105:787-91
15. Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res 2001;51:391-402
16. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287:860-7
17. Palm C, Pistrosch F, Herbrig K, et al. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 2006:119(7A):S87-92
18. Costello-Boerrigter LC, Smith WB, Boerringter G, et al. Vasopressin 2 receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal 2006;290:F273-8
19. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112
20. Targowla R. Des troubles fonctionnel du rein dans les maladies mentales. L'excretion del'eau [Kidney malfunction and mental illness: water excretion]. Bull Soc Med Hop Paris 1923;47:1711-13
21. Hoskins RG. Schizophrenia from the physiological point of view. Ann Intern Med 1933;7:445-56
22. Barrahal HS. Water intoxication in a mental case. Psychiat Quart 1938;12:767-71
23. Jose CJ, Perez-Cruet J. Incidence and morbidity of self-induced water intoxication in state mental hospital patients. Am J Psychiatry 1979;136:221-2
24. Okura M, Morii S. Polydipsia, polyuria and water intoxication observed in psychiatric inpatients. Tokushima J Exp Med 1986;33:1-5
25. Evenson RC, Jos CJ, Mallya AR. Prevalence of polydipsia among public psychiatric patients. Psychol Rep 1987;60:803-7
26. Emsley RA, Van de Meer H, Aalbers C, et al. Inappropriate antidiuretic state in long-term psychiatric inpatients. South African Med J 1990;77:307-8
27. Bremner A, Reagan A. Polydipsia and water intoxication in a mental handicap hospital. Br J Psychiatry 1991;158:244-50
28. Peh LH, Devan GS, Eu PW. Water intoxication in psychiatric patients in Singapore. Singapore Med J 1990;31:238-41
29. Shah PJ, Greenberg WM. Polydipsia with hyponatremia in a state hospital population. Hosp Comm Psychiatry 1992;43:509-11
30. de Leon J, Dadvand D, Canuso C, et al. Polydipsia and water intoxication in a long-term psychiatric hospital. Biol Psychiatry 1996;40:28-34
31. Josiassen RC. Schizophrenia and the problem of hyponatremia. Presentation to the US Food and Drug Administration (FDA) Advisory Committee on Cardiovascular and Renal Drugs, 24 June 2008, Washington D.C., USA
32. Koczapski AB, Millson RC. Individual differences in serum sodium levels in schizophrenic men with self-induced water intoxication. Am J Psychiatry 1989;146:1614-15
33. Siegler EL, Tamres D, Berlin JA, et al. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med 1995;155:953-7
34. Siegel AJ. Hyponatremia in psychiatric patients: update on evaluation and management. Harv Rev Psychiatry 2008:16;13-24
35. Nicolson SE, Mayberg HS, Pennell PB, et al. Persistent auditory hallucinations that are unresponsive to antipsychotic drugs. Am J Psychiatry 2006;163:1153-9
36. Fraser CL, Arieff AI. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997;102:67-77
37. Hoorn EJ, Zietse R. Hyponatremia revisited: translating physiology to practice. Nephron Physiol 2008;108:46-59
38. May DL. The relationship between self-induced water intoxication and severity of psychiatric symptoms. Arch Psychiatr Nurs 1998;12:335-43
39. Goldman MB, Robertson GL, Luchins DJ, et al. Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. Arch Gen Psychiatry 1997;54:443-9
40. Inoue K, Tadai T, Kamimura H. The syndrome of self-induced water intoxication in psychiatric patients. Folia Psychiatrica et Neurologica Japonica 1985;39:121-8
41. Cosgray RE, Hanna V, Davidhizar RE, et al. The water intoxicated patient. Arch Psychiatr Nurs 1990;4:308-12
42. Vieweg WVR, David JJ, Rowe WT, et al. Death from self-induced water intoxication among patients with schizophrenic disorders. J Nerv Ment Dis 1985;173:161-5
43. Kushnir M, Schattner A, Ezri T, et al. Schizophrenia and fatal self-induced water intoxication with appropriately diluted urine. Am J Med Sci 1990;300:385-7
44. Schnur DB, Wirkowski E, Reddy R, et al. Cognitive impairments in schizophrenic patients with hyponatremia. Biol Psychiatry 1993;33:836-8
45. Shutty MS, Briscoe L, Sautter S, et al. Neuropsychological manifestations of hyponatremia in chronic schizophrenic patients with the syndrome of psychosis, intermittent hyponatremia and polydipsia (PIP). Schizophr Res 1993;10:125-30
46. Emsley RA, Spangenberg JJ, Roberts MC, et al. Disordered water homeostasis and cognitive impairment in schizophrenia. Biol Psychiatry 1993;34:630-3
47. Emsley RA, Roberts MC, Smith R, et al. Disordered water homeostasis in schizophrenia and cerebral ventricular size. Br J Psychiatry 1995;166:501-6
48. Schnur DB, Smith S. The polydipsia-hyponatremia syndrome and cognitive impairment: pathophysiological implications. In: Schnur D, Kirch DG, editors, Water balance in schizophrenia. American Psychiatric Press, Washington, DC; 1996. p. 147-63
49. Torres IJ, Keedy S, Marlow-O'Connor M, et al. Neuropsychological impairment in patients with schizophrenia and evidence of hyponatremia and polydipsia. Neuropsychology 2009;23:307-14
50. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am J Med 2006;119:71.e1-71e.8
51. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006;119(7A):S79-82
52. Bissram M, Scott FD, Liu L, et al. Risk factors for symptomatic hyponatremia: the role of pre-existing asymptomatic hyponatremia. Intern Med J 2007;37:149-55
53. Baker EA, Tian Y, Adler S, et al. Blood-brain barrier disruption and complement activation in the brain following rapid correction of chronic hyponatremia. Exp Neurol 2000;165:221-30
54. Erhardt VR, Goldman MB. Drug-induced endocrine dysfunction. In: Keshavan MS, Kennedy J, editors, Drug-induced dysfunction in psychiatry: diagnosis and management. Hemisphere Publications, Washington, DC; 1991. p. 295-310
55. Goldman MB, Luchins DJ, Robertson GL. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med 1988;318:397-403
56. Delva NJ, Crammer JL, Lawson JS, et al. Vasopressin in chronic psychiatric patients with primary polydipsia. Br J Psychiatry 1990;157:703-12
57. Linquette M, Fossati P, Lefebvre J, et al. Acute water intoxication from compulsive drinking. Br Med J 1973;2:365
58. Hariprasad MK, Eisinger RP, Nadler IM, et al. Hyponatremia in psychogenic polydipsia. Arch Intern Med 1980;140:1639-42
59. Vieweg WV, Rowe WT, David JJ, et al. Oral sodium chloride in the management of schizophrenic patients with self-induced water intoxication. J Clin Psychiatry 1985;46:16-9
60. Goldman MB, Mitchell CP. What is the functional significance of hippocampal pathology in schizophrenia? Schizophr Bull 2004;30:367-92
61. Goldman MB, Torres IJ, Keedy S, et al. Reduced anterior hippocampal formation volume in hyponatremic schizophrenic patients. Hippocampus 2007;17:554-62
62. Suzuki M, Takeuchi O, Mori I, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with schizophrenia. Biol Psychiatry 1992;31:1057-61
63. Umbricht DS, Saltz B, Pollack S, et al. Polydipsia and tardive dyskinesia in chronic psychiatric patients-related disorders? Am J Psychiatry 1993;150:1536-8
64. Canuso CM, Goldman MB. Does minimizing neuroleptic dosage influence hyponatremia? Psychiat Res 1996;63:227-9
65. Jessani M, Montgomery J, Fedde JD, et al. Lack of association between antipsychotics and hyponatremia in chronic schizophrenia. Schizophr Res 2006;84:307-9
66. Goldman MB, Robertson GL, Luchins DJ, et al. The influence of polydipsia on water excretion in hyponatremic, polydipsic schizophrenic patients. J Clin Endocr Metab 1998;81:1465-70
67. Blum A, Tempey FW, Lynch WJ. Somatic findings in patients with psychogenic polydipsia. J Clin Psychiatry 1983;44:55-6
68. Schoos R, Cohen CI. Medical co-morbidity in older persons with schizophrenia. In: Cohen CI, editor, Schizophrenia in later life: treatment, research and policy. American Psychiatric Publishing, Washington, DC; 2003. p. 113-38
69. Hawken ER, Crookall JM, Reddick D, et al. Mortality over a 20-year period in patients with primary polydipsia associated with schizophrenia: a retrospective study. Schizophr Res 2009;107:128-33
70. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997;171:502-8
71. Brookes G, Ahmed AG. Pharmacological treatments for psychosis-related polydipsia. Cochrane Database Syst Rev 2006;4:CD003544
72. Weise WJ, Rimmer JM, Hood VL. Tolvaptan for hyponatremia. N Engl J Med 2007;356:961
73. Gheorghiade M, Orlandi C, Burnett JC Jr, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 2005;11:260-9
74. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrin Metab Clin 2001;30:671-94
75. Josiassen RC, Goldman M, Jessani M, et al. Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia. Biol Psychiatry 2008;64:1097-100
76. Keefe RSE, Goldberg TE, Harvey PD, et al. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68:283-97
77. Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 2008;3:331-6
78. Package insert for SAMSCA™ (tolvaptan) tablets. Initial US Approval: May 2009